The Effect of Mianserin on Alpha-2 Adrenergic Receptor Function in Depressed Patients

1984 ◽  
Vol 144 (4) ◽  
pp. 407-416 ◽  
Author(s):  
Dennis S. Charney ◽  
George R. Heninger ◽  
David E. Sternberg
Keyword(s):  
Blood Pressure ◽  
Growth Hormone ◽  
Adrenergic Receptor ◽  
Hormone Secretion ◽  
Growth Hormone Secretion ◽  
Term Treatment ◽  
Receptor Function ◽  
Depressed Patients ◽  
Long Term Treatment

SummaryRecent clinical investigations have shown that long term treatment with the tricyclic antidepressants desipramine and amitriptyline reduces the sensitivity of the alpha-2 adrenergic autoreceptor. In order to determine whether the tetracyclic antidepressant mianserin also has this action, the effect of clonidine, an alpha-2 adrenergic receptor agonist, on plasma levels of the norepinephrine metabolite 3-methoxy-4-hydroxyphenlethyleneglycol (MHPG), blood pressure, and patient-rated sedation were measured in fifteen depressed patients before and during mianserin treatment. Postsynaptic alpha-2 adrenergic receptor function was assessed by measuring the growth hormone response to clonidine before and during treatment. Mianserin had little or no effect on the ability of clonidine to lower plasma MHPG and blood pressure, and to increase sedation and growth hormone secretion. The findings of this investigation indicates that long term mianserin treatment does not produce significant subsensitivity of the alpha-2 adrenergic receptor and suggests that a reduction in alpha-2 adrenergic autoreceptor sensitivity is not a necessary action for all effective antidepressant treatments.

Long-term treatment with growth hormone of children with short stature and normal growth hormone secretion

1992 ◽  
Vol 120 (5) ◽  
pp. 702-708 ◽  
Author(s):  
Wayne V. Moore ◽  
Karl C. Moore ◽  
Rachel Gifford ◽  
Joseph G. Hollowell ◽  
David L. Donaldson
Keyword(s):  
Growth Hormone ◽  
Short Stature ◽  
Hormone Secretion ◽  
Growth Hormone Secretion ◽  
Normal Growth ◽  
Term Treatment ◽  
Long Term Treatment

LONG-TERM TREATMENT OF ACROMEGALY WITH BROMOCRIPTINE

1978 ◽  
Vol 87 (4) ◽  
pp. 687-700 ◽  
Author(s):  
Peter Claes Eskildsen ◽  
Per Aaby Svendsen ◽  
Lisbeth Vang ◽  
Jørn Nerup
Keyword(s):  
Growth Hormone ◽  
Hormone Secretion ◽  
Visual Fields ◽  
Growth Hormone Secretion ◽  
Term Treatment ◽  
Prolactin Secretion ◽  
Plasma Growth Hormone ◽  
Free Cortisol ◽  
Long Term Treatment

ABSTRACT Treatment with bromocriptine, 30–55 mg daily, in 13 acromegalics for 1–15 months, resulted in a 60 % decrease in growth hormone secretion, as judged from the excretion of growth hormone in 24-h urine. Normal excretion was obtained in 10 patients, while 1 patient showed no response. The plasma growth hormone response to O-GTT was improved, but not normalized, in 4 of 7 patients treated for more than 6 months, and marked glucosuria disappeared in two diabetics. While the secretion of TSH, LH and FSH was unchanged, the prolactin secretion was inhibited. The urine excretion of free cortisol showed a 30 % decrease, possibly due to a direct effect of bromocriptine on the ACTH-secretion. Hypercalcaemia was never seen, but the initial hypercalcuria showed a modest decrease without measurable changes in the creatinine clearance. The subjective relief during long-term treatment was marked in 10 of 11 patients and the dominating symptoms disappeared in 40–67 %, whereas heal-pad thickness, enlarged sellae, and visual fields remained unchanged. No serious side effects were observed. Treatment with bromocriptine seems effective and should be considered as a remedy amongst others, in suitable cases of acromegaly.

Abstract P053: Enhanced Exercise Capacity By Muscadine Grape Extract Treatment Is Only Evident In Older Hypertensive Female Rats And Is Independent Of Blood Pressure

Hypertension ◽  
2020 ◽  
Vol 76 (Suppl_1) ◽  
Author(s):  
Nildris Cruz Diaz ◽  
A'ja V Duncan ◽  
Wayne Graham ◽  
Brian Westwood ◽  
Patricia E. Gallagher ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Exercise Capacity ◽  
Physical Performance ◽  
Term Treatment ◽  
Female Rats ◽  
Sprague Dawley ◽  
Grape Extract ◽  
Long Term Treatment ◽  
Muscadine Grape

Physical performance and systolic blood pressure (SBP) during aging in normotensive female Sprague-Dawley (SD) and hypertensive (mRen2)27 transgenic rats were assessed following long-term treatment with a Muscadine Grape Extract (MGE, Piedmont Research and Development Corp). MGE was administered at a dose of 0.2 mg/mL in the drinking water starting at 14 weeks (wks) of age with an endpoint at 70 wks of age (total time of treatment of 56 wks). At 20-, 40- and 70-wks of age, physical performance (exercise capacity in seconds and workload in grams - meters) was determined using a treadmill at a velocity of 17 cm/second with a 5% incline. SBP was determined by tail-cuff plethysmography in trained rats. There were no significant differences in physical performance between SD and (mRen2)27 female rats at any age despite the higher SBP in the (mRen2)27 rats at all ages. Long-term treatment with MGE had no significant effect on physical performance or SBP in SD rats at any age. In contrast, MGE treatment markedly increased exercise capacity (40 wks: 1615 ± 166 vs 4943 ± 442 seconds, p<0.01, n = 4-9; 70 wks: 2520 ± 374 vs 4117 ± 245 seconds, p<0.01, n = 4-8) and workload (40 wks: 4579 ± 490 vs 14730 ± 1353 grams - meters, p<0.01, n = 4-9; 70 wks: 8338 ± 1340 vs 13659 ± 933 grams - meters, p<0.01, n = 4-8) at the later ages in female (mRen2)27 rats, while there was no effect on SBP (20 wks: 167 ± 4 vs 173 ± 4 mm Hg, n = 4-6; 40 wks: 177 ± 8 vs 170 ± 7 mm Hg, n = 6-7; 70 wks:154 ± 6 vs 172 ± 6 mm Hg, n = 5) at any age. These data suggest that MGE treatment is effective in improving physical performance only in hypertensive female rats and may be independent of changes in blood pressure. The benefit of MGE in the older hypertensive female may reflect reductions in vascular stiffness and oxidative stress. Support: Chronic Disease Research Fund, Hypertension & Vascular Research Center

Hormonal changes in gilts receiving bromocriptine orally during gestation

2000 ◽  
Vol 80 (2) ◽  
pp. 373-376 ◽  
Author(s):  
S. Horth ◽  
C. Farmer
Keyword(s):  
Growth Hormone ◽  
Key Words ◽  
Initial Treatment ◽  
Term Treatment ◽  
Hormonal Changes ◽  
Long Term Treatment ◽  
Blood Profiles

Pregnant gilts received a placebo (CTL; n = 7) or 10 mg of bromocriptine orally (Bromo; n = 7) thrice daily from days 70 to 107 of gestation. Blood profiles of prolactin (PRL), growth hormone (GH) and cortisol were obtained on day 70, after the first treatment with bromocriptine, and on day 107 of gestation. On day 70, concentrations of PRL, GH and cortisol were not affected (P > 0.1) by bromocriptine. By day 107, bromocriptine decreased concentrations of PRL (P < 0.01) whereas concentrations of GH and cortisol were not affected (P > 0.1). Results indicate that long-term treatment with bromocriptine inhibits PRL secretion without affecting GH and cortisol concentrations, while no changes are present within 8 h of initial treatment. Key words: Gilt, gestation, bromocriptine, prolactin

Sign in / Sign up

Export Citation Format

Share Document